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Objective: To study role of tiroﬁban in postinfarction angina who
refused for early intervention.
Methodology: (1) Single centre prospective trial. (2) Duration of
study – December 2013 to June2015. (3) Total of 212 patients of
postinfarction angina who refused to undergo early intervention
after thrombolysis included in this study. (4) Follow up for 30 days.
(5) They are assigned in 1:1 manner to receive either tiroﬁban
intravenously 25 mg/kg over 3 min and then 0.15 mg/kg/min (or
0.075 mg/kg/min for patients with serum creatinine >1.5 mg%),
for up to 18 h along with intensiﬁcation of antianginal therapy
(group A – 106 patients) OR intensiﬁed antianginal therapy alone
(group B – 106 patients). (6) Patients were well matched according
to baseline characteristics.
Inclusion criteria: (1) Written informed consent. (2) Patients with
STEMI (anterior and inferior both) presenting in emergency within
12 h of chest pain thrombolysed exclusively with Streptokinase
(stk+) who had recurrent episodes of angina within 48 h of admis-
sion.
Exclusion criteria: (1) Hypersensitivity, history of thrombocytope-
nia with tiroﬁban. (2) Active/history of internal bleeding (within
last 30 days), intracranial hemorrhage, or neoplasm. (3) History of
stroke within last 30 days or any history of hemorrhagic stroke. (4)
AV malformation or aneurysm, aortic dissection, severe HTN,
acute pericarditis. (5) Current use of another parenteral glycopro-
tein IIb/IIIa inhibitor. (6) Patient age <18 yrs and >75 yrs.
Primary endpoints: Composite of all cause mortality and nonfatal
myocardial infarction at 30 days.
Secondary endpoints: (1) Recurrent episodes of angina. (2) Total
time to reach pain free status.
Results: Primary composite endpoints did not differ between 2
groups – 20 patients (18.86%) versus 21 patients (19.81%) reached
primary endpoints in groupAand group Bwith p value of 0.26, odds
ratio (OR) 0.82. Recurrent angina was lower in group A – 10 patients
(9.43%) versus 21 patients (19.81%) with p value of 0.003. Total time
to reach pain free status was lower in group A when compared to
group B with p value of 0.05 mean time of 18 hrs and 30 min in
group A as compared to 43 hrs and 18 min in group B. Minor
bleeding were higher with tiroﬁban (16.98% in group A versus
7.54% in group B) with p value 0.003 according to GUSTO bleeding
classiﬁcation. However more serious bleed did not differ between
two groups.
Conclusion: (1) Patients with postinfarction angina, unwilling
for intervention, had reduced incidence of recurrent angina
and earlier relief of anginal symptoms, when tiroﬁban added to
intensiﬁed antianginal therapy. (2) This is achieved without caus-
ing signiﬁcant difference in primary composite endpoint. (3)
Although signiﬁcant increase in minor bleed is noted, incidence
of major bleed did not differ between two groups.
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Background: (1) Following percutaneous coronary intervention
(PCI), clopidogrel therapy in addition to aspirin leads to greater
protection from thrombotic complications than aspirin alone.
Whether triple antiplatelet therapy with addition of cilostazol is
superior or similar to dual antiplatelet therapy in patients with
acute coronary syndrome undergoing PCI in the era of drug-eluting
stents remains unclear. (2) It inhibits platelet aggregation and is a
direct arterial vasodilator. Its main effects are dilation of the
arteries supplying blood to the legs and decreasing platelet coa-
gulation. (3) Because of its differentmechanism of action cilostazol
may have add on antiplatelet effect in patients undergoing PCI.
Objectives: To evaluate the effect of triple antiplatelet versus dual
antiplatelet therapy in patients with acute coronary syndrome
after PCI.
Inclusion criteria: Patients 18 years and above acute coronary
syndrome STEMI (AWMI & IWMI both) presented in emergency
within 12 h of chest pain.
Exclusion criteria: Contraindication to aspirin, clopidogrel, cilos-
tazol, left main disease, graft vessel disease, LVEF <30%.
Methods: We collected consecutive 280 acute coronary syndrome
patients between December 2013 and June 2015 undergoing drug-
eluting stents implantation in our hospital. They received either
dual (aspirin plus clopidogrel; dual group; n = 140) or triple (aspirin
plus clopidogrel plus cilostazol; triple group; n = 140) antiplatelet
therapy. Patients were well matched according to baseline char-
acteristics. The triple group received additional cilostazol at least
for 1 month. Various major adverse cardiac events at 6 months
were compared between these 2 groups.
Primary endpoints: Total deaths, cardiac deaths, and MACC.
Secondary endpoints: (1) Ischemia driven target lesion revascular-
isation and ischemia driven target vessel revascularisation at 6
months (2) Stent thrombosis.
Results: (1) Patientswith STEMIwho underwent primary PCIwith a
drug-eluting stent, after 6months of treatment, the group assigned
to cilostazol in addition to dual antiplatelet therapy for at least one
month (n = 35) had reduced cardiac death (adjusted OR = 0.52; 95%
CI, 0.32–0.84), p value – 0.04, total death (adjusted OR = 0.6; 95% CI,
0.41–0.89) p value – 0.02, and total major adverse cardiac events
(adjusted OR = 0.74; 95% CI, 0.58–0.95). (2) Incidence of TLR & TVR
did not decrease signiﬁcantly with p values 0.52 and 0.45, respec-
tively. (3) However, incidence of stent thrombosis reduced but
results were not signiﬁcant with p value 0.09. (4) The ﬁndings
supported the safety of triple antiplatelet therapy, as the adverse
effect proﬁle of the triple antiplatelet therapy group was not sig-
niﬁcantly different from that of the dual antiplatelet therapy group
(major bleedings: 2.1% in the cilostazol group vs. 2.8% in the dual
therapy group). (5) Patients who beneﬁted the most from triple
therapy were women, patients aged older than 65 years, and
patients with diabetes.
Conclusions: Triple antiplatelet therapy seems to be superior to
dual antiplatelet therapy in patients with ACS undergoing PCI with
drug-eluting stents with insigniﬁcant difference in adverse effect
proﬁle.
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Sudden cardiac death is the most feared outcome of ST elevation
myocardial infarction (STEMI). Major cardiac arrhythmia occurring
very early after STEMI are harbinger of sudden cardiac death (SCD).
We conducted a study to record cardiac arrhythmia within 3 h of
thrombolysis in 100 patients of STEMI by applying 24 h Holter
recording. The patient admitted to ICCU were clinically examined,
thrombolysed with tenecteplase or streptokinase, put on 24 h
Holter monitoring and studied for major adverse coronary events
(MACE) during hospital stay and up to 1 month after discharge.
Mean age of study population was 56.75  15.6 yrs with male (76%)
predominating. One ormoremajor cardiac risk factor was noted in
74% patients with chronic smoking detected in 79%. Door to needle
time was 4.76  2.5 h. 59% had anterior location while 49% had
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